FABP5 and Glucose intolerance: ,37, 38, 39 For example, semaglutide reduces the expression of CD36, FABP5, ACSL, ACOX3, PLIN2, ANGPTL4, LPL, MGLL, AQP7 and PDK4 involved in lipid metabolism accompanied by decreases in visceral fat accumulation and blood lipids, and improvement in glucose intolerance.38